MannKind (MNKD) Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MNKD shares.
View MNKD analyst ratings or view top-rated stocks.

1 equities research analysts have issued twelve-month price targets for MannKind's stock. Their MNKD share price forecasts range from $6.00 to $7.00. On average, they predict the company's share price to reach $6.50 in the next twelve months. This suggests a possible upside of 51.2% from the stock's current price.
View analysts price targets for MNKD or view top-rated stocks among Wall Street analysts.

MannKind's stock was trading at $5.27 at the start of the year. Since then, MNKD stock has decreased by 18.4% and is now trading at $4.30.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our MNKD earnings forecast.

MannKind Co. (NASDAQ:MNKD) posted its quarterly earnings data on Tuesday, May, 9th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating analysts' consensus estimates of ($0.05) by $0.01. The biopharmaceutical company earned $40.63 million during the quarter, compared to the consensus estimate of $37.40 million. The business's revenue for the quarter was up 238.8% on a year-over-year basis. During the same period last year, the firm earned ($0.10) EPS.

ETFs with the largest weight of MannKind (NASDAQ:MNKD) stock in their portfolio include SPDR S&P Biotech ETF (XBI), ALPS Medical Breakthroughs ETF (SBIO), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Future Gen 200 ETF (QQQS), Principal Healthcare Innovators ETF (BTEC), Invesco DWA SmallCap Momentum ETF (DWAS), Global X Aging Population ETF (AGNG) and iShares Micro-Cap ETF (IWC).

Based on aggregate information from My MarketBeat watchlists, some companies that other MannKind investors own include Bausch Health Companies (BHC), Novavax (NVAX), Geron (GERN), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD), Chesapeake Energy (CHKAQ), Micron Technology (MU), NVIDIA (NVDA), Intel (INTC) and Gilead Sciences (GILD).

MannKind trades on the NASDAQ under the ticker symbol "MNKD."

MannKind's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (7.83%), State Street Corp (6.77%), Davidson Kempner Capital Management LP (0.00%), Geode Capital Management LLC (1.95%), Emerald Advisers LLC (1.38%) and Two Sigma Investments LP (1.16%). Insiders that own company stock include Alejandro Galindo, Anthony C Hooper, David Thomson, Michael Castagna, Steven B Binder, Stuart A Tross and Stuart A Tross.
View institutional ownership trends.

Shares of MNKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MNKD stock can currently be purchased for approximately $4.30.

MannKind (NASDAQ:MNKD) has a market capitalization of $1.14 billion and generates $99.77 million in revenue each year. The biopharmaceutical company earns $-87,400,000.00 in net income (profit) each year or ($0.28) on an earnings per share basis.

The company employs 348 workers across the globe.

MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. The official website for the company is www.mannkindcorp.com. The biopharmaceutical company can be reached via phone at (818) 661-5000, via email at ir@mannkindcorp.com, or via fax at 661-775-2081.